Brian J. Hall · 19 obras en el catálogoObrasPerformance managementDermatopathologyDDiagnostic Pathology : Nonneoplastic DermatopathologyDiagnostic Pathology : Nonneoplastic DermatopathologyDiagnostic PathologyCCutaneous Drug EruptionsCutaneous Drug EruptionsSSkin InfectionsSkin InfectionsCCirconCirconTThe lending view of the monetary transmission mechanismThe lending view of the monetary transmission mechanismRRisk-taking incentives and the cost of insurance company faiRisk-taking incentives and the cost of insurance company failuresAAre CEOs really paid like bureaucrats?Are CEOs really paid like bureaucrats?MManaging option fragilityManaging option fragilityTThe myth of the patient JapaneseThe myth of the patient JapaneseOOptimal exercise prices for executive stock optionsOptimal exercise prices for executive stock optionsTThe pay to performance incentives of executive stock optionsThe pay to performance incentives of executive stock optionsRRegulatory free cash flow and the high cost of insurance comRegulatory free cash flow and the high cost of insurance company failuresSSix challenges in designing equity-based paySix challenges in designing equity-based paySStock options for undiversified executivesStock options for undiversified executivesTThe taxation of executive compensationThe taxation of executive compensationTThe trouble with stock optionsThe trouble with stock options
DDiagnostic Pathology : Nonneoplastic DermatopathologyDiagnostic Pathology : Nonneoplastic Dermatopathology
TThe lending view of the monetary transmission mechanismThe lending view of the monetary transmission mechanism
RRisk-taking incentives and the cost of insurance company faiRisk-taking incentives and the cost of insurance company failures
OOptimal exercise prices for executive stock optionsOptimal exercise prices for executive stock options
TThe pay to performance incentives of executive stock optionsThe pay to performance incentives of executive stock options
RRegulatory free cash flow and the high cost of insurance comRegulatory free cash flow and the high cost of insurance company failures